TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8793701
Drug: Non-pharmacological management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological management (dietary therapy, restriction of alcohol consumption, exercise)
Study: 8793701
Drug: Non-pharmacological management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological management (restriction of sodium intake, behavioral therapy)
Study: 6500764
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg per day
Study: 6500764
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg per day
Study: 30478021
Drug: M-CT (mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-CT (mobile cognitive therapy) with minimal therapist support added to treatment as usual (TAU)
Study: 25486369
Drug: Borderline B12
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Borderline B12 concentrations (148 to 221 pmol/L)
Study: 25486369
Drug: Low B12
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low B12 (<148 pmol/L)
Study: 22475985
Drug: Buprenorphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine plus ultra-low-dose naloxone (0.3 mg + 0.02 mg)
Study: 22475985
Drug: Buprenorphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine alone (0.3 mg)
Study: 20532452
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg orally one hour prior to imaging
Study: 16234574
Drug: Active 40
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active 40 KHz ultrasound therapy delivered by a saline mist
Study: 12399142
Drug: ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine (0.3 mg/kg; intravenous)
Study: 12399142
Drug: haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2 mg) + ketamine (0.3 mg/kg; intravenous)
Study: 7572966
Drug: Vaccine for
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine for Haemophilus influenzae type b (Hib)
Study: 2301090
Drug: Metoprolol (Seloken)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (Seloken) administered once or twice daily
Study: 31543373
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2 g, ×2)
Study: 31543373
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil, 2 g ×2)
Study: 31024122
Drug: Reduced receptor
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced receptor type‐specific actions of dopamine in women
Study: 31024122
Drug: Reduced receptor
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced receptor type‐specific actions of dopamine in men
Study: 23812551
Drug: Arginine-supplemented enteral
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-supplemented enteral nutrition (9.0 g/L)
Study: 21367943
Drug: Casein (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (20 g)
Study: 21367943
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate (20 g)
Study: 19737620
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 mcg) once daily
Study: 19737620
Drug: Ipratropium (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (26 mcg)/Albuterol (206 mcg), 2 actuations 4 times daily
Study: 17403721
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (9 mg/L vs. 7.8 mg/L, P = 0.002)
Study: 17403721
Drug: MCP-1 levels
Normalized name: MCPA TRIISOPROPANOLAMINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP-1 levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (190.6 pg/mL vs. 170.8 pg/mL, P = 0.04)
Study: 17403721
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein levels in diabetic patients vs. non-diabetic patients in TACTICS-TIMI 18 (6.6 mg/L vs. 5.2 mg/L, P = 0.0005)
Study: 17403721
Drug: Risk associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk associated with a 1 mmol/L increase in glucose among those with CRP greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with CRP less than the median (HR 1.02, 95% CI 0.97-1.06)
Study: 15110367
Drug: Cisatracurium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.015 mg.k(‐1)
Study: 15110367
Drug: Rocuronium 0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.09 mg.k(‐1)
Study: 11255446
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/d followed by 10 mg/d
Study: 8423906
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg twice a day
Study: 8423906
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg twice a day
Study: 24731498
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (n = 192)
Study: 24731498
Drug: Antibiotics (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n = 134)
Study: 20588187
Drug: 0.6 mg/h
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/h transdermal nitroglycerin (TGTN)
Study: 20588187
Drug: 0.05 mg/h
Normalized name: fentanyl 0.05 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/h transdermal nitroglycerin (TGTN)
Study: 20588187
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin and inhaled salbutamol
Study: 18217157
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Study: 18841285
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD)
Study: 11371659
Drug: Combined immunoadsorption
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunoadsorption and intravenous immunoglobulins (n=17)
Study: 11371659
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of immunoglobulins at a dose of 0.14 g/kg
Study: 11371659
Drug: Immunoglobulin administration
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin administration
Study: 2956870
Drug: Enoximone (MDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (MDL 17,043) 50, 75, 100, 150 or 200 mg (mean dose 1.46 +/- 0.16 mg/kg)
Study: 30037519
Drug: NIPPV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPPV with nasal cannula (NC) at 15 L/min of oxygen
Study: 23690996
Drug: Severity-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity-based treatment protocols
Study: 23690996
Drug: Treatment (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specific gene expression profiling)
Study: 9411502
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy (0.4 mg/kg every 12 hours for 2 days, started 10 minutes before the first antibiotic dose)
Study: 25546177
Drug: Sono-electro-magnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sono-electro-magnetic therapy
Study: 21385862
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of rosuvastatin added to 80 mg/day of valsartan (ARB)
Study: 21385862
Drug: ARB monotherapy
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB monotherapy (80 mg/day of valsartan)
Study: 8690778
Drug: Dog and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog and monkey sera used as blocking antibodies against mouse anti-hsCR1 monoclonal antibodies
Study: 8690778
Drug: Mouse, rat,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouse, rat, dog antibodies
Study: 1930618
Drug: Biperiden 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 6 mg
Study: 7049075
Drug: Topical poly(ICLC)
Normalized name: poly ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical poly(ICLC)
Study: 20391735
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mg/kg and Propofol 2 mg/kg (group PRO)
Study: 20391735
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mg/kg and Sevoflurane 5% in a 1:2 mixture of oxygen and nitrous oxide (group SEVO)
Study: 18165765
Drug: Subcutaneous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous alemtuzumab (30 mg doses on days 0 and 1)
Study: 15226321
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus thalidomide 200 mg orally each day
Study: 15226321
Drug: docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 30 mg/m(2) intravenously every week for 3 consecutive weeks
Study: 11566519
Drug: LEC removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEC removal from the entire anterior capsule (Group C)
Study: 9631312
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg bid for 4 weeks plus amoxicillin 500 mg qid for 2 weeks
Study: 9631312
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg bid for 4 weeks and placebo qid for 2 weeks
Study: 9631312
Drug: Placebo bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid for 4 weeks and amoxicillin 500 mg qid for 2 weeks
Study: 14707892
Drug: Computer-assisted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-assisted insulin dose adjustment
Study: 10513041
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg PYR
Study: 2050326
Drug: S‐adenosyl‐L‐methionine, 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐adenosyl‐L‐methionine, 900 mg, administered via daily intravenous infusions for 20 days
Study: 2050326
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via daily intravenous infusions for 20 days
Study: 6402356
Drug: Anticonvulsant medication
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant medication (phenobarbitone) during pregnancy
Study: 6402356
Drug: Anticonvulsant medication
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant medication (multiple agents) during pregnancy
Study: 6402356
Drug: Anticonvulsant medication
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant medication during pregnancy
Study: 30523758
Drug: NAB-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAB-paclitaxel 100 mg/m2 plus gemcitabine 1,000 mg/m2 (arm B)
Study: 30523758
Drug: NAB-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB-paclitaxel 125 mg/m2 plus gemcitabine 1,000 mg/m2 (arm D)
Study: 25901642
Drug: Keratin gel
Normalized name: gold keratinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keratin gel
Study: 25901642
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream (Control)
Study: 24364085
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL saline solution)
Study: 16881463
Drug: Weight-bearing MWM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-bearing MWM treatment technique
Study: 16881463
Drug: Non-weight-bearing MWM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-weight-bearing MWM treatment technique
Study: 11170060
Drug: Interferon-alpha 2B
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2B therapy
Study: 2458094
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (intravenous administration)
Study: 2458094
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride with beta-blocker or serotonin antagonist pretreatment
Study: 29391008
Drug: Home fortification
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home fortification with iron-containing micronutrient powders (two different formulations)
Study: 23275352
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment for 12 weeks
Study: 17681544
Drug: BRT (capnometry‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRT (capnometry‐assisted breathing therapy)
Study: 17681544
Drug: Delayed‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed‐treatment control group
Study: 12602447
Drug: Temazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (30 mg) administered before daytime sleep
Study: 12602447
Drug: Placebo (lactose-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose-filled capsule)
Study: 10981531
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 500 microg three times per day for 7 days (Group II)
Study: 10981531
Drug: Nebulized budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized budesonide, 500 microg twice per day for two months (Group III)
Study: 10981531
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment only (Group I)
Study: 8915143
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) 1% aqueous solution
Study: 18675974
Drug: Ultrashort flare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist
Study: 11957318
Drug: Polyester clothing
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester clothing with low moisture absorption and high air permeability (B clothing)
Study: 11957318
Drug: Cotton clothing
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton clothing with high moisture absorption and high air permeability (C clothing)
Study: 7755827
Drug: Topical lidocaine-epinephrine
Normalized name: epinephrine / lidocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-epinephrine (TLE)
Study: 2270298
Drug: Crystalline penicillin
Normalized name: Crystalline penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline penicillin (i.v. infusions for 10 days, daily dose of 20-24 mega U., combined with probenecid, followed by i.m. procaine penicillin in daily dose of 1.2 mega U., total dose 12-50 mega U.)
Study: 2270298
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin (i.m. in daily dose of 1.2 mega U., total dose 24-60 mega U.)
Study: 31002442
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy pain management programme (CBT-PMP), six modules delivered once weekly.
Study: 15635800
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 96% ethanol into the cyst after evaluation under ultrasonographic control
Study: 9385973
Drug: Smooth implants
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth implants
Study: 18157310
Drug: Spherical orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spherical orbital implant
Study: 18157310
Drug: Quad-motility orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad-motility orbital implant
Study: 18157310
Drug: Both spherical
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both spherical and quad-motility orbital implants
Study: 15329588
Drug: Morphine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.75 microg x kg(‐1) x min(‐1)
Study: 11345288
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) nasal spray, 200 microg daily for 2 weeks
Study: 9202835
Drug: Pentoxifylline 1200
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 1200 mg/day for 6 months
Study: 7526102
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of GSNO starting 10 min before PTCA
Study: 7526102
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (7 patients receiving standard treatment with aspirin, glyceryl trinitrate, and heparin)
Study: 3299004
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 2.5 mg/day
Study: 25917024
Drug: Aqueous povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aqueous povidone-iodine solution (Group I)
Study: 25917024
Drug: Alcoholic povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic povidone-iodine solution (Group II)
Study: 20500100
Drug: Low-dose polytherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose polytherapy (metformin 850 mg/day, flutamide 62.5 mg/day, pioglitazone 7.5 mg/day, ethinylestradiol 20 μg/day, drospirenone 3 mg/day)
Study: 20500100
Drug: Low-dose polytherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose polytherapy
Study: 10357340
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM administered 30 min before skin incision (Group B)
Study: 10357340
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM administered after gallbladder removal (Group A)
Study: 10357340
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CPM) 20 mg IM administered 30 min before skin incision (Control group)
Study: 1771934
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg/d for 4 weeks (n = 13)
Study: 1771934
Drug: bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12)
Study: 1771934
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)
Study: 7137520
Drug: Terbutaline inhalations
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhalations (5 doses)
Study: 24894410
Drug: Freeze-dried broccoli
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried broccoli sprouts (90 mg of active sulforaphane, 15 capsules per day)
Study: 24894410
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive substances, mainly methylcellulose, same capsule size and portion distribution)
Study: 22277664
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml kg(‐1) diluted raspberry syrup
Study: 22277664
Drug: 7 ml
Normalized name: ethanol 7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml kg(‐1) diluted raspberry syrup
Study: 20625111
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target dose 0.4 mg . kg(‐1) . d(‐1))
Study: 15793606
Drug: HR 0‐(beta‐hydroxyethyl)‐rutosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 0‐(beta‐hydroxyethyl)‐rutosides (1 g/day)
Study: 15793606
Drug: HR 0‐(beta‐hydroxyethyl)‐rutosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 0‐(beta‐hydroxyethyl)‐rutosides (2 g/day)
Study: 10431768
Drug: Interferon-beta1a treatment
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta1a treatment
Study: 7593528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg gemeprost by vaginal pessary (group I)
Study: 2259825
Drug: Fenoterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2.5 mg) with saline to complete 3 ml given through a jet nebulizer; followed by an additional dose (1 mg) through a 500 ml spacer 30 minutes later
Study: 2259825
Drug: Fenoterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2.5 mg) with saline to complete 3 ml given through a spacer first; followed by an additional dose (1 mg) through a jet nebulizer 30 minutes later
Study: 6357964
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate tablets